AtaiBeckley Inc. (NASDAQ:ATAI) shares are up on Wednesday following the announcement of promising Phase 2a results for its treatment-resistant depression drug, BPL-003.

Depression Drug Shows Sustained Antidepressant Response

The company reported a 66.7% antidepressant response rate at Day 2, which has contributed to the stock's upward momentum as broader markets experienced gains on Tuesday.

AtaiBeckley announced that a single intranasal dose of BPL-003 achieved significant reductions in MADRS scores among participants with treatment-resistant depression, with 83% of patients maintaining a response at Week 12.

BPL-003 was generally well tolerated with no serious adverse events reported, and participants achieved a mean discharge time of approximately 100 minutes post-dose.

The company is on track to initiate Phase 3 studies in the second quarter of 2026, following recent FDA alignment.

Pipeline Progress Includes EMP-01 In Social Anxiety Disorder

In February, AtaiBeckley shared topline results from an exploratory Phase 2a trial of EMP-01, an oral R-MDMA treatment for Social Anxiety Disorder.

In the trial, 49% of patients receiving EMP-01 were rated as "very much improved" or "much improved," compared to only 15% in the placebo group, indicating a clinically meaningful improvement.

AtaiBeckley Technical Setup Signals Near-Term Momentum With Mixed Trend

At $4.09, the stock is trading 12.8% above its 20-day simple moving average (SMA) and 6% above its 100-day SMA, suggesting strong short-term momentum.

However, the 50-day SMA is still below the current price, indicating a mixed trend in the intermediate term.

The relative strength index (RSI) is at 53.63, which is neutral and suggests that the stock is neither overbought nor oversold. This positioning indicates a balanced buyer-seller dynamic, allowing for potential upward movement if positive sentiment continues.

  • Key Resistance: $4.50 — A level where selling pressure may increase.
  • Key Support: $3.50 — A level where buying interest could emerge.

The stock has shown a remarkable 12-month performance of 213.22%, reflecting strong long-term growth potential.

Currently, it is trading near the midpoint of its 52-week range, which suggests that while there is room for growth, the stock is not at an extreme high or low.

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $14.20. Recent analyst moves include:

  • Deutsche Bank: Initiated with Buy (Target $12.00) (March 27)
  • HC Wainwright & Co.: Buy (Maintains Target to $25.00) (March 17)
  • Needham: Buy (Maintains Target to $14.00) (March 9)

Benzinga Edge Rankings

Below is the Benzinga Edge scorecard for AtaiBeckley, highlighting its strengths and weaknesses compared to the broader market:

  • Momentum: Bullish (Score: 91.36) — Stock is outperforming the broader market.

The Verdict: AtaiBeckley's Benzinga Edge signal reveals a strong momentum-driven story, reflecting its recent positive developments and potential for growth in a challenging sector.

ATAI Price Action: AtaiBeckley shares were up 0.13% at $3.79 at the time of publication on Wednesday, according to Benzinga Pro data.

Image via Shutterstock